Osaka, Japan

Hisashi Takasugi


Average Co-Inventor Count = 4.2

ph-index = 21

Forward Citations = 1,325(Granted Patents)


Inventors with similar research interests:


Location History:

  • Suminoe, JP (1984)
  • Hamagutinishi, JP (1985 - 1987)
  • Hamaguchinishi, JP (1984 - 1988)
  • Kohamanishi, JP (1980 - 1997)
  • Sakai, JP (1993 - 2008)
  • Osaka, JP (1979 - 2009)

Company Filing History:


Years Active: 1979-2009

Loading Chart...
Areas of Expertise:
Hdac Inhibitor
Propanolamine Derivatives
Cyclic Hexapeptides
Cephem Compounds
Guanidine Derivatives
Polypeptide Compounds
Thiazole Derivatives
Pyrimidoindole Derivatives
Benzazole Compounds
N-Containing Heterocyclic Compounds
Nitro Compounds
Therapeutic Agents
137 patents (USPTO):Explore Patents

Title: Hisashi Takasugi: Pioneering Innovator in Pharmaceutical Research

Introduction:

In the world of pharmaceutical research, Hisashi Takasugi, hailing from Osaka, Japan, has emerged as a prominent inventor and contributor to the field. With an impressive number of patents to his name and a career spanning multiple renowned companies, Takasugi has made significant contributions to the development of novel HDAC inhibitors. In this article, we delve into his latest patents, career highlights, notable collaborations, and salute his remarkable contributions to the pharmaceutical industry.

Latest Patents:

Hisashi Takasugi's most recent patents revolve around HDAC inhibitors - compounds that have shown promising potential for treating various diseases. One such patent relates to compounds having the formula (I), while another patent focuses on a specific compound with the formula (I). Takasugi's work in this area showcases his dedication to discovering innovative solutions for medical challenges.

Career Highlights:

Takasugi's career has been marked by his association with renowned pharmaceutical companies, where he has honed his expertise and contributed significantly to groundbreaking research. He has worked at Fujisawa Pharmaceutical Company, Ltd., known today as Astellas Pharma Inc., and Astellas Pharma Gmbh, a subsidiary of Astellas Pharma Inc. Throughout his career, Takasugi has explored various areas of drug discovery, with a particular focus on HDAC inhibitors.

Collaborations:

Collaborations often serve as the breeding ground for fruitful innovation, and Hisashi Takasugi's inventiveness has been nurtured through his collaborations with talented individuals. Two notable coworkers who have contributed to his journey are Takao Takaya and Takashi Masugi. These collaborations have promoted the exchange of ideas and fostered an environment conducive to pushing the boundaries of pharmaceutical research.

Conclusion:

Hisashi Takasugi's remarkable career and extensive patent portfolio portray him as a pioneering figure in pharmaceutical research. With his latest patents in the realm of HDAC inhibitors, Takasugi exemplifies dedication to advancing medical science and improving patient outcomes. His contributions, alongside collaborations with fellow researchers, have undoubtedly set a high benchmark for innovation in the field. Takasugi's work serves as an inspiration for aspiring inventors and underscores the importance of continuous exploration and research in the quest for groundbreaking pharmaceutical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…